Ebola treatment, mAb114, safe in adults
by Press Release from Outbreak News Today on (#47SYW)
The investigational Ebola treatment mAb114 is safe, well-tolerated, and easy to administer, according to findings from an early-stage clinical trial published in The Lancet. Eighteen healthy adults received the monoclonal antibody as part of a Phase 1 clinical trial that began in May 2018 at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. ["]
The post Ebola treatment, mAb114, safe in adults appeared first on Outbreak News Today.